Table 3.
Comparison of characteristics of patients with uveitis
| Characteristics | (1) Uveitis with Systemic immune-mediated disease, n = 44 | (2) JIA-related uveitis, n = 23 | (3) Idiopathic uveitis, n = 101 |
p-value [(1) vs. (3)] |
p-value [(2) vs. (3)] |
|---|---|---|---|---|---|
| Sex, N(%) | |||||
| Male | 25 (56.8) | 15 (65.2) | 48 (47.5) | 0.303 | 0.126 |
| Female | 19 (43.2) | 8 (34.8) | 53 (52.5) | ||
| Median age at uveitis diagnosis, y (IQR) | 13.0 (10.0–16.0) | 11.0 (6.5–16.0) | 13.0 (10.0–16.0) | 0.914 | 0.251 |
| Laboratory findings | |||||
| HLA-B27 tested, N | 27 | 16 | 43 | ||
| Positive, N (%) | 8 (29.6) | 7 (43.8) | 5 (11.6) | 0.059 | 0.006 |
| HLA-B51 tested, N | 18 | 5 | 41 | ||
| Positive, N (%) | 5 (27.8) | 1 (20.0) | 7 (17.1) | 0.347 | 0.871 |
| RF tested, N | 41 | 23 | 71 | ||
| Positive, N (%) | 5 (12.2) | 3 (13.0) | 5 (7.0) | 0.357 | 0.370 |
| ANA tested, N | 40 | 23 | 66 | ||
| Positive, N (%) | 16 (40.0) | 13 (56.5) | 17 (25.8) | 0.125 | 0.007 |
| Type, N (%) | |||||
| Unilateral | 18 (40.9) | 15 (65.2) | 54 (53.5) | 0.164 | 0.306 |
| Bilateral | 26 (59.1) | 8 (34.8) | 47 (46.5) | ||
| Location, N (%) | |||||
| Anterior | 22 (50.0) | 13 (56.5) | 52 (51.5) | 0.633 | 0.779 |
| Intermediate | 1 (2.3) | 1 (4.4) | 9 (8.9) | ||
| Posterior | 1 (2.3) | 0 (0.0) | 2 (2.0) | ||
| Panuveitis | 14 (31.8) | 5 (21.7) | 25 (24.8) | ||
| Unknown | 6 (13.6) | 4 (17.4) | 13 (12.9) | ||
| Treatment, N (%) | |||||
| Topical steroid | 44 (100.0) | 23 (100.0) | 101 (100.0) | ||
| Systemic steroid | 37 (84.1) | 20 (87.0) | 35 (34.6) | < 0.001 | < 0.001 |
| Synthetic DMARDs | 31 (70.5) | 17 (73.9) | 15 (14.9) | < 0.001 | < 0.001 |
| Biological DMARDs | 11 (25.0) | 6 (26.1) | 0 (0.0) | < 0.001 | < 0.001 |
| Ocular complications, N (%) | 21 (47.7) | 11 (47.8) | 35 (34.7) | 0.137 | 0.238 |
y years, JIA juvenile idiopathic arthritis, IQR interquartile range, HLA human leukocyte antigen, RF rheumatoid factor, ANA antinuclear antibody, DMARDs disease-modifying antirheumatic drugs